drugset / Trial / NCT03903926

Efficacy Trial of a Commercial EV71 Vaccine

NCT03903926

Phase 4 Completed 15500 enrolled Sinovac Biotech Co., Ltd
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this post-marketing study is to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine post marketing, and explore the protective levels of various enterovirus neutralizing antibodies

Timeline

Start
2019-03-26
Primary completion
2020-06-30
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject EV71 vaccine Vaccine